Teva Doubles Down On Alvotech Biosimilars Partnership
Invests $40m, Adds Two More Biosimilars To Deal And Actively Supports Quality Efforts
Teva will get more involved in Alvotech’s quality oversight as part of enhancements to the pair’s US biosimilars collaboration that will also see two products added to the deal, as well as a $40m investment in Alvotech from the Israeli giant.
